Apotex completes acquisition of Searchlight

TORONTO — Apotex Inc. announced the successful completion of its acquisition of Searchlight Pharma Inc., a Canadian specialty branded pharmaceutical company. This acquisition accelerates the company’s growth within the specialty branded pharmaceutical market. Searchlight is now operating as the Specialty Pharma Division of Apotex and will be led by Mark Nawacki, President of Searchlight.

Apotex’s background in generic and biosimilar pharmaceuticals, combined with Searchlight’s branded product portfolio, enhances the company’s position as a pharmaceutical manufacturer in Canada. “This strategic move aligns with our vision to better serve patients and consumers along their health journey by adding a diverse portfolio of value add and specialty innovative branded products,” stated Allan Oberman, President and CEO of Apotex. “We are pleased to welcome Searchlight to the Apotex team and look forward to leveraging the synergies between our teams to accelerate our continued growth.”

On May 24, 2024, Apotex entered its 50th year of business, marking an achievement rooted in pharmaceutical products. Apotex has consistently expanded access to complex health products and says they remain committed to creating new products that address unmet medical needs, facilitating improved global access to essential pharmaceuticals.

“Building on our 50-year legacy, this acquisition supports our renewed strategic focus to diversify beyond traditional generic pharmaceuticals, positioning Apotex as a Health Partner of Choice in the Americas,” added Mr. Oberman.